In today’s briefing:
- Genda IPO – Dreams of Reviving the Domestic Arcade Industry with a Roadmap of Doing so as Well
- Fadu IPO – Thoughts on Valuation
- Nusantara Sejahtera Raya (Cinema XXI) IPO – Peer Comparison
- Nusantara Sejahtera Raya (Cinema XXI) IPO – Thoughts on Valuation
- Pre-IPO InSilico Medicine – AI Pharmaceutical Is Immature; Valuation Expansion Relies on Imagination
Genda IPO – Dreams of Reviving the Domestic Arcade Industry with a Roadmap of Doing so as Well
- Genda Inc (9166 JP) is looking to raise around US$100m in its Japan IPO.
- Genda develops and operates amusement facilities in Japan, primarily operating under its Genda GiGO Entertainment subsidiary.
- As of Apr 23, the firm operated 250 amusement facilities domestically and four facilities in Taiwan.
Fadu IPO – Thoughts on Valuation
- Fadu (440110 KS) is looking to raise up to US$147m in its Korean IPO.
- Fadu is a South Korean fabless semiconductor maker mainly engaged in flash storage technology innovation. Its core products are Enterprise Solid State Drive (SSD) and Enterprise SSDs.
- In our previous notes, we looked at the company’s past performance and undertook a peer comparison. In this note, we talk about valuation.
Nusantara Sejahtera Raya (Cinema XXI) IPO – Peer Comparison
- Cinema XXI (CINEMA IJ) aims to raise up to US$160m in its Indonesia IPO.
- Cinema XXI is a premium theatrical exhibition, F&B and experience company. It is the largest cinema chain operator in Indonesia.
- We have looked at the company’s past performance in our earlier notes. In this note, we will undertake a peer comparison.
Nusantara Sejahtera Raya (Cinema XXI) IPO – Thoughts on Valuation
- Cinema XXI (CINEMA IJ) aims to raise up to US$160m in its Indonesia IPO.
- Cinema XXI is a premium theatrical exhibition, F&B and experience company. It is the largest cinema chain operator in Indonesia.
- We have looked at the company’s past performance and undertaken a peer comparison in our earlier notes. In this note, we talk about valuations.
Pre-IPO InSilico Medicine – AI Pharmaceutical Is Immature; Valuation Expansion Relies on Imagination
- InSilico ’s business model is more of AI-CXO + AI-SaaS, but hasn’t reached the stage of AI-biotech, considering its current revenue streams, which may lead to InSilico ultimately changing its positioning.
- The significance of pipeline lies in the need for InSilico to verify the effectiveness of AI platforms/algorithms/technology through successful product launch. However, valuation of InSilico could be different from biotech.
- AI pharmaceutical industry is at its infancy, which is a far cry from current levels of investment and expectations in the sector.We advise investors to be rational about this field.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
